- Oops!Something went wrong.Please try again later.
Inovio Pharmaceuticals Inc (NASDAQ: INO) is trading higher Thursday after the company announced it received regulatory authorization from Brazil's ANVISA to initiate the global Phase 3 segment of its Phase 2/3 trial for INO-4800, its DNA vaccine candidate for COVID-19.
The global Phase 3 segment of the Phase 2/3 clinical trial will evaluate the efficacy of INO-4800 in a two-dose regimen.
Inovio said the primary endpoint of the case-driven Phase 3 trial is virologically confirmed COVID-19.
"Inovio's focus on supporting the global response to the pandemic is unwavering – and will bring forward the potential advantages of INO-4800, which in addition to being well-tolerated with balanced neutralizing antibodies and T cell responses, has a strong thermostability profile and potentially offers the ability to serve as both a primary as well as a booster vaccine," said Joseph Kim, president and CEO of Inovio.
Inovio is a U.S.-based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and other infectious diseases.
INO Price Action: Inovio has traded as high as $19 and as low as $5.81 over a 52-week period.
At last check Thursday, the stock was up 8.18% at $9.13.
Photo: courtesy of Inovio.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.